Compare Davita Inc (DVA) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Robinhood Markets, Inc. — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Robinhood Markets, Inc. trades at $108.99 (market cap $98.46B). The key difference: Robinhood Markets, Inc. is far larger — about 8.7× Davita Inc's market cap, and Davita Inc is more actively traded (650,294 versus 18,771,023). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Robinhood Markets, Inc. for 75 Days on average.
| DVA | HOOD | |
|---|---|---|
Market Cap | $11.28B | $98.46B |
Volume | 650,294 | 18,771,023 |
Sector | Health | Financials |
52-Week High | $240.96 | $152.46 |
52-Week Low | $103.87 | $65.16 |
Typical Hold Time | 113 Days | 75 Days |
Enterprise Value | $24.00B | $105.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Robinhood (HOOD) trades at $109.51, down 2.22% today, with strong technical support at $108. The stock shows robust fundamentals with 2025 revenue reaching $4.47B and net income of $1.88B, representing 42% margins. Recent news highlights expansion into 24/7 stock trading and new product launches, positioning the company for continued growth in the e-brokerage sector.
Wall Street maintains a bullish outlook with 77% buy ratings and a $137 consensus price target, representing 25% upside potential. Key risks include valuation concerns with a 48.5 P/E ratio and execution challenges in new product rollouts. The company's transformation into a broader financial services platform provides long-term growth opportunities despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
